Cybin Inc. Advances Phase 3 Psychedelic Therapeutics Program, Signaling Progress in Mental Health Treatment
Cybin Inc. reports significant progress in its Phase 3 clinical trials for CYB003, a novel treatment for major depressive disorder, highlighting the potential of psychedelic therapeutics in addressing mental health conditions.
